ArticleJournal of diabetes investigation2022

Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes.

Eiichi Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.